All In Biotech

Drug Trial Radar · NCT04165317

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,068 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,068

Actual

Start

Dec 30, 2019

Primary completion

Dec 2, 2024

Study completion Dec 2, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B). In Part A (enrollment closed), each participant was assigned to one of three study treatment groups. * One group is given sasanlimab and BCG at the study clinic. * The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only. * The third group is given BCG only and will not receive sasanlimab. In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor. \- Both groups will be given sasanlimab at the study clinic. On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B. The decision to discontinue enrollment to Part B was not made for safety reasons.

Conditions

  • Non-muscle Invasive Bladder Cancer

Interventions

  • PF-06801591Drug

    A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.

  • Bacillus Calmette-GuerinDrug

    Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm CTime frame: From randomization (Day 1) to first documentation of high-grade disease, progression of disease, persistence of CIS or death due to any cause, whichever occurred first (maximum follow up duration was up to 257.1 weeks)

Locations

195 sites in 14 countries. Site status is shown where the registry gives one.

  • Arizona Urology Specialists

    Tucson, Arizona

  • Arkansas Urology

    Little Rock, Arkansas

  • Koman Family Outpatient Pavilion

    La Jolla, California

  • Sulpizio Cardiovascular Center at UC San Diego Health

    La Jolla, California

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • University of California Irvine Medical Center

    Orange, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • The Urology Center of Colorado

    Denver, Colorado

  • Urological Research Network Corp

    Hialeah, Florida

  • UF Health Jacksonville

    Jacksonville, Florida

  • UF Health North

    Jacksonville, Florida

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois

  • DuPage Medical Group

    Lisle, Illinois

  • DuPage Medical Group Ambulatory Surgery Center

    Lombard, Illinois

  • DuPage Medical Group

    Lombard, Illinois

  • Edward Hospital

    Naperville, Illinois

  • Ochsner LSU Health Shreveport - Regional Urology

    Shreveport, Louisiana

  • Chesapeake Urology Research Associates

    Hanover, Maryland

  • Michigan Institute of Urology, PC

    Troy, Michigan

  • Bellevue Hospital

    New York, New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York

  • NYU Langone Medical Center (Tisch Hospital)

    New York, New York

  • NYU Langone Health Urology Associates

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Premier Medical Group of the Hudson Valley PC

    Poughkeepsie, New York

  • Associated Medical Professionals of New York, PLLC

    Syracuse, New York

  • Montefiore Medical Center - Montefiore Medical Park

    The Bronx, New York

  • Montefiore Medical Center - Oncology Investigational Services

    The Bronx, New York

  • VA Portland Healthcare System

    Portland, Oregon

  • AUC Urologists LLC

    Murrells Inlet, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Parkway Surgery Center

    Myrtle Beach, South Carolina

  • Atlantic Urology Clinics South Strand Office

    Myrtle Beach, South Carolina

  • Urology Clinics of North Texas

    Dallas, Texas

  • Baylor University Medical Center

    Dallas, Texas

  • Urology Clinics of North Texas

    Dallas, Texas

  • Houston Metro Urology

    Houston, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Urology San Antonio PA

    San Antonio, Texas

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.